Alpha-Ketoglutaric Acid

Alpha-Ketoglutaric Acid

SCHEMBL2030659

O=C(O)C(=O)COP(=O)(O)O.O=C(O)CCC(=O)C(=O)O

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 2/20 0.56
MAPK1 P28482 1/20 0.56
SLC13A3 Q8WWT9 1/20 0.56
OR51E2 Q9H255 1/20 0.56
TPI1 P60174 2/20 0.41
LMNA P02545 3/20 0.36
ALKBH5 Q6P6C2 1/20 0.36
SUCNR1 Q9BXA5 1/20 0.36
PGK1 P00558 1/20 0.35
PGK2 P07205 1/20 0.35
PEPD P12955 1/20 0.34
PGD P52209 1/20 0.33
FOLH1 Q04609 1/20 0.31
MVD P53602 1/20 0.31
MEN1 O00255 1/20 0.30
HPGD P15428 1/20 0.30
TSHR P16473 1/20 0.30
BLM P54132 1/20 0.30
KMT2A Q03164 1/20 0.30
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL50365 0.87 TPI1 (0.50) OR51E2TPI1PGK1PGK2PEPD
Alpha-Ketoglutaric Acid SCHEMBL28457662 0.80 EGLN1 (0.78) EGLN1MAPK1SLC13A3OR51E2LMNA
SCHEMBL2030661 0.78 TPI1 (0.36) EGLN1MAPK1SLC13A3OR51E2TPI1
Glutamic Acid SCHEMBL345401 0.78 GRM8 (0.56) FOLH1BLMKMT2A
Alpha-Ketoglutaric Acid SCHEMBL7057149 0.75 MAPK1 (0.45) EGLN1MAPK1SLC13A3OR51E2PGK1
Dexfosfoserine SCHEMBL439230 0.75 MAPK1 (0.45) EGLN1MAPK1SLC13A3OR51E2PGK1
Alpha-Ketoglutaric Acid SCHEMBL17127347 0.75 EGLN1 (1.00) EGLN1MAPK1SLC13A3OR51E2LMNA
Alpha-Ketoglutaric Acid SCHEMBL932116 0.75 EGLN1 (1.00) EGLN1MAPK1SLC13A3OR51E2LMNA
Alpha-Ketoglutaric Acid SCHEMBL3776640 0.75 EGLN1 (1.00) EGLN1MAPK1SLC13A3OR51E2LMNA
Alpha-Ketoglutaric Acid SCHEMBL7400 0.75 EGLN1 (1.00) EGLN1MAPK1SLC13A3OR51E2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9834773-B2 Methods and means for metabolic engineering and improved product formation by micro-organisms UNIVERSITEIT LEIDEN (NL) 2017-12-05 US disclosed
US-20110143394-A1 Methods and Means for Metabolic Engineering and Improved Product Formation by Micro-Organisms UNIVERSITEIT LEIDEN (NL) 2011-06-16 US disclosed
WO-2007094667-A9 METHODS AND MEANS FOR METABOLIC ENGINEERING AND IMPROVED PRODUCT FORMATION BY MICRO-ORGANISMS UNIV LEIDEN (NL) 2009-01-29 WO disclosed
EP-1818398-A1 Methods and means for metabolic engineering and improved product formation by micro-organisms Universiteit Leiden (NL) 2007-08-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110143394-A1 Methods and Means for Metabolic Engineering and Improved Product Formation by Micro-Organisms DCXR, GNPAT, GRHPR EGLN1 4053/4885MAPK1 4652/4885SLC13A3 4525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.